Skip to main content
Top
Published in: Virchows Archiv 3/2016

01-09-2016 | Original Article

Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer

Authors: Trevor A. Flood, Nicola Schieda, Daniel T. Keefe, Rodney H. Breau, Chris Morash, Kevin Hogan, Eric C. Belanger, Kien T. Mai, Susan J. Robertson

Published in: Virchows Archiv | Issue 3/2016

Login to get access

Abstract

Selected patients with Gleason score (GS) 3 + 4 = 7 prostate cancer (PCa) detected on transrectal ultrasound (TRUS)-guided biopsies may be considered for active surveillance (AS); however, a proportion of these will harbor more aggressive disease. The purpose of this study was to determine if morphologies of Gleason pattern 4 PCa may predict upgrading and/or upstaging after radical prostatectomy (RP). A database search for men with GS 3 + 4 = 7 PCa diagnosed on TRUS-guided biopsy that underwent RP between January 2010 and October 2015 identified 152 patients. Two blinded genitourinary pathologists independently reviewed the biopsies and assessed ill-defined glands (IDG), fused glands, small or large cribriform patterns, and glomerulations. Patient age, serum prostate-specific antigen (PSA), percentage (%) of biopsy sites involved by 3 + 4 = 7 PCa, and overall extent of pattern 4 were also recorded. GS and stage (presence or absence of extraprostatic extension [EPE]) were retrieved from RP reports. Data were compared using independent t tests and chi-square. Inter-observer agreement was calculated using Cohen’s Kappa statistic. Percent of biopsy sites and extent of pattern 4 were compared to statistically significant morphologies using the Spearman correlation. 28.3 % (43/152) of patients were upgraded to GS >3 + 4 = 7 at RP (GS 4 + 3 = 7 [N = 17], GS 4 + 3 = 7 with tertiary pattern 5 [N = 25], and GS 4 + 5 = 9 [N = 1]) and 44.1 % (67/152) showed EPE after RP. PSA was associated with both upgrading (8.5 ± 5.4 vs. 6.9 ± 3.2 ng/mL, [p = 0.04]) and EPE (8.2 ± 4.6 vs. 6.7 ± 3.2 ng/mL, [p = 0.03]). IDG, fused glands, and glomerulations were not associated with upgrading or EPE (p > 0.05) with moderate to strong inter-observer agreement (K = 0.76–0.88). There was strong inter-observer agreement for small and large cribriform formations (K = 0.93 and 0.94, respectively) and both patterns were strongly associated with upgrading (p < 0.001) and EPE (p = 0.02) on RP. Strong associations were observed between increasing number of morphologies and both upgrading (p = 0.0.25) and EPE (p < 0.001). Overall extent of pattern 4 was associated with upgrading (p = 0.009) and EPE (p = 0.019) while percent of sites involved by GS 3 + 4 = 7 was only associated with EPE (p = 0.023). Cribriform morphology correlated to percentage of sites with 3 + 4 and overall extent of pattern 4 (rho = 0.25, p = 0.002, rho = 0.20, p = 0.015, respectively). Presence of cribriform morphology on TRUS-guided biopsy is strongly associated with upgrading and upstaging at RP and shows near-perfect inter-observer agreement whereas IDG, fused glands, and glomerulations were not useful. Cribriform morphology may be of importance when considering treatment plans for patients with intermediate risk PCa.
Literature
2.
go back to reference Ploussard G et al. (2011) The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 60(2):291–303CrossRefPubMed Ploussard G et al. (2011) The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 60(2):291–303CrossRefPubMed
3.
go back to reference Dall’Era MA et al. (2012) Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 62(6):976–983CrossRefPubMed Dall’Era MA et al. (2012) Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 62(6):976–983CrossRefPubMed
4.
go back to reference Stattin P et al. (2010) Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 102(13):950–958CrossRefPubMedPubMedCentral Stattin P et al. (2010) Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 102(13):950–958CrossRefPubMedPubMedCentral
5.
go back to reference Bangma CH et al. (2013) Active surveillance for low-risk prostate cancer. Crit Rev Oncol Hematol 85(3):295–302CrossRefPubMed Bangma CH et al. (2013) Active surveillance for low-risk prostate cancer. Crit Rev Oncol Hematol 85(3):295–302CrossRefPubMed
6.
go back to reference Klotz L (2015) Active surveillance and focal therapy for low-intermediate risk prostate cancer. Transl Androl Urol 4(3):342–354PubMedPubMedCentral Klotz L (2015) Active surveillance and focal therapy for low-intermediate risk prostate cancer. Transl Androl Urol 4(3):342–354PubMedPubMedCentral
7.
go back to reference Morash C et al. (2015) Active surveillance for the management of localized prostate cancer: guideline recommendations. Can Urol Assoc J 9(5–6):171–178CrossRefPubMedPubMedCentral Morash C et al. (2015) Active surveillance for the management of localized prostate cancer: guideline recommendations. Can Urol Assoc J 9(5–6):171–178CrossRefPubMedPubMedCentral
8.
go back to reference Klotz L et al. (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28(1):126–131CrossRefPubMed Klotz L et al. (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28(1):126–131CrossRefPubMed
9.
go back to reference van As NJ et al. (2008) Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 54(6):1297–1305CrossRefPubMed van As NJ et al. (2008) Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 54(6):1297–1305CrossRefPubMed
10.
go back to reference van den Bergh RC et al. (2007) Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 52(6):1560–1563CrossRefPubMed van den Bergh RC et al. (2007) Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 52(6):1560–1563CrossRefPubMed
11.
go back to reference van den Bergh RC et al. (2009) Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men. BJU Int 103(11):1472–1477CrossRefPubMed van den Bergh RC et al. (2009) Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men. BJU Int 103(11):1472–1477CrossRefPubMed
12.
go back to reference Epstein JI et al. (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61(5):1019–1024CrossRefPubMedPubMedCentral Epstein JI et al. (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61(5):1019–1024CrossRefPubMedPubMedCentral
13.
go back to reference Huang CC et al. (2014) Gleason score 3 + 4 = 7 prostate cancer with minimal quantity of Gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen. Am J Surg Pathol 38(8):1096–1101PubMed Huang CC et al. (2014) Gleason score 3 + 4 = 7 prostate cancer with minimal quantity of Gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen. Am J Surg Pathol 38(8):1096–1101PubMed
14.
go back to reference Epstein JI et al. (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9):1228–1242CrossRefPubMed Epstein JI et al. (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9):1228–1242CrossRefPubMed
15.
go back to reference Iczkowski KA et al. (2011) Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol 136(1):98–107CrossRefPubMedPubMedCentral Iczkowski KA et al. (2011) Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol 136(1):98–107CrossRefPubMedPubMedCentral
16.
go back to reference Keefe DT et al. (2015) Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy. Virchows Arch 467(4):437–442CrossRefPubMed Keefe DT et al. (2015) Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy. Virchows Arch 467(4):437–442CrossRefPubMed
17.
go back to reference Siadat F et al. (2015) Not all Gleason pattern 4 prostate cancers are created equal: a study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series. Prostate 75(12):1277–1284CrossRefPubMed Siadat F et al. (2015) Not all Gleason pattern 4 prostate cancers are created equal: a study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series. Prostate 75(12):1277–1284CrossRefPubMed
18.
go back to reference Kryvenko ON et al. (2013) Gleason score 7 adenocarcinoma of the prostate with lymph node metastases: analysis of 184 radical prostatectomy specimens. Arch Pathol Lab Med 137(5):610–617CrossRefPubMed Kryvenko ON et al. (2013) Gleason score 7 adenocarcinoma of the prostate with lymph node metastases: analysis of 184 radical prostatectomy specimens. Arch Pathol Lab Med 137(5):610–617CrossRefPubMed
19.
go back to reference Bastian PJ et al. (2009) Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 55(6):1321–1330CrossRefPubMed Bastian PJ et al. (2009) Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 55(6):1321–1330CrossRefPubMed
20.
go back to reference Conti SL et al. (2009) Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 181(4):1628–1633 discussion 1633-4 CrossRefPubMed Conti SL et al. (2009) Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 181(4):1628–1633 discussion 1633-4 CrossRefPubMed
21.
go back to reference Eggener SE et al. (2009) A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 181(4):1635–1641 discussion 1641 CrossRefPubMedPubMedCentral Eggener SE et al. (2009) A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 181(4):1635–1641 discussion 1641 CrossRefPubMedPubMedCentral
22.
go back to reference van den Bergh RC et al. (2010) Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study. BJU Int 105(7):956–962CrossRefPubMed van den Bergh RC et al. (2010) Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study. BJU Int 105(7):956–962CrossRefPubMed
23.
go back to reference Kweldam CF et al. (2015) Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod Pathol 28(3):457–464CrossRefPubMed Kweldam CF et al. (2015) Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod Pathol 28(3):457–464CrossRefPubMed
24.
go back to reference Egevad L et al. (2011) Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading. Virchows Arch 459(2):175–182CrossRefPubMed Egevad L et al. (2011) Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading. Virchows Arch 459(2):175–182CrossRefPubMed
25.
go back to reference Dong F et al. (2013) Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma. Am J Surg Pathol 37(12):1855–1861CrossRefPubMed Dong F et al. (2013) Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma. Am J Surg Pathol 37(12):1855–1861CrossRefPubMed
26.
go back to reference Qian J, Jenkins RB, Bostwick DG (1997) Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod Pathol 10(11):1113–1119PubMed Qian J, Jenkins RB, Bostwick DG (1997) Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod Pathol 10(11):1113–1119PubMed
27.
go back to reference Herawi M, Epstein JI (2007) Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate. Am J Surg Pathol 31(6):889–894CrossRefPubMed Herawi M, Epstein JI (2007) Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate. Am J Surg Pathol 31(6):889–894CrossRefPubMed
28.
go back to reference Pacelli A et al. (1998) Prostatic adenocarcinoma with glomeruloid features. Hum Pathol 29(5):543–546CrossRefPubMed Pacelli A et al. (1998) Prostatic adenocarcinoma with glomeruloid features. Hum Pathol 29(5):543–546CrossRefPubMed
Metadata
Title
Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer
Authors
Trevor A. Flood
Nicola Schieda
Daniel T. Keefe
Rodney H. Breau
Chris Morash
Kevin Hogan
Eric C. Belanger
Kien T. Mai
Susan J. Robertson
Publication date
01-09-2016
Publisher
Springer Berlin Heidelberg
Published in
Virchows Archiv / Issue 3/2016
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-016-1981-2

Other articles of this Issue 3/2016

Virchows Archiv 3/2016 Go to the issue

Review and Perspectives

The spectrum of ectopic thymomas